BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 31030380)

  • 1. Pegaspargase: A Review in Acute Lymphoblastic Leukaemia.
    Heo YA; Syed YY; Keam SJ
    Drugs; 2019 May; 79(7):767-777. PubMed ID: 31030380
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial.
    Place AE; Stevenson KE; Vrooman LM; Harris MH; Hunt SK; O'Brien JE; Supko JG; Asselin BL; Athale UH; Clavell LA; Cole PD; Kelly KM; Laverdiere C; Leclerc JM; Michon B; Schorin MA; Welch JJ; Lipshultz SE; Kutok JL; Blonquist TM; Neuberg DS; Sallan SE; Silverman LB
    Lancet Oncol; 2015 Dec; 16(16):1677-90. PubMed ID: 26549586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcome of pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated Erwinia asparaginase, pegcrisantaspase: A report from the Children's Oncology Group.
    Rau RE; Dreyer Z; Choi MR; Liang W; Skowronski R; Allamneni KP; Devidas M; Raetz EA; Adamson PC; Blaney SM; Loh ML; Hunger SP
    Pediatr Blood Cancer; 2018 Mar; 65(3):. PubMed ID: 29090524
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pegaspargase: an alternative?
    Holle LM
    Ann Pharmacother; 1997 May; 31(5):616-24. PubMed ID: 9161659
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PEGylated
    Verma A; Chen K; Bender C; Gorney N; Leonard W; Barnette P
    Pediatr Hematol Oncol; 2019 Aug; 36(5):277-286. PubMed ID: 31296092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pegaspargase: a review of clinical studies.
    Graham ML
    Adv Drug Deliv Rev; 2003 Sep; 55(10):1293-302. PubMed ID: 14499708
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FDA drug approval summary: pegaspargase (oncaspar) for the first-line treatment of children with acute lymphoblastic leukemia (ALL).
    Dinndorf PA; Gootenberg J; Cohen MH; Keegan P; Pazdur R
    Oncologist; 2007 Aug; 12(8):991-8. PubMed ID: 17766659
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic and pharmacodynamic properties of calaspargase pegol Escherichia coli L-asparaginase in the treatment of patients with acute lymphoblastic leukemia: results from Children's Oncology Group Study AALL07P4.
    Angiolillo AL; Schore RJ; Devidas M; Borowitz MJ; Carroll AJ; Gastier-Foster JM; Heerema NA; Keilani T; Lane AR; Loh ML; Reaman GH; Adamson PC; Wood B; Wood C; Zheng HW; Raetz EA; Winick NJ; Carroll WL; Hunger SP
    J Clin Oncol; 2014 Dec; 32(34):3874-82. PubMed ID: 25348002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics-based integration of multiple doses of intravenous pegaspargase in a pediatric regimen for adults with newly diagnosed acute lymphoblastic leukemia.
    Douer D; Aldoss I; Lunning MA; Burke PW; Ramezani L; Mark L; Vrona J; Park JH; Tallman MS; Avramis VI; Pullarkat V; Mohrbacher AM
    J Clin Oncol; 2014 Mar; 32(9):905-11. PubMed ID: 24516026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Efficacy observation of polyethylene glycol conjugated asparaginase for induction treatment of children with newly diagnosed acute lymphoblastic leukemia].
    Liu F; Wan Y; Chang L; Guo Y; Yang W; Wang S; Chen X; Liu T; Ruan M; Zhang L; Liu X; Zou Y; Chen Y; Zhu X
    Zhonghua Er Ke Za Zhi; 2014 Mar; 52(3):215-7. PubMed ID: 24824393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic leukemia.
    Douer D; Yampolsky H; Cohen LJ; Watkins K; Levine AM; Periclou AP; Avramis VI
    Blood; 2007 Apr; 109(7):2744-50. PubMed ID: 17132721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pegaspargase hypersensitivity reactions: intravenous infusion versus intramuscular injection - a review.
    Beaupin LK; Bostrom B; Barth MJ; Franklin I; Jaeger R; Kamath P; Schreiber B; Bleyer A
    Leuk Lymphoma; 2017 Apr; 58(4):766-772. PubMed ID: 27643446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study.
    Avramis VI; Sencer S; Periclou AP; Sather H; Bostrom BC; Cohen LJ; Ettinger AG; Ettinger LJ; Franklin J; Gaynon PS; Hilden JM; Lange B; Majlessipour F; Mathew P; Needle M; Neglia J; Reaman G; Holcenberg JS; Stork L
    Blood; 2002 Mar; 99(6):1986-94. PubMed ID: 11877270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Asparaginase Erwinia chrysanthemi (Erwinaze®): a guide to its use in acute lymphoblastic leukemia in the USA.
    Keating GM
    BioDrugs; 2013 Aug; 27(4):413-8. PubMed ID: 23794007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Erwinia asparaginase achieves therapeutic activity after pegaspargase allergy: a report from the Children's Oncology Group.
    Salzer WL; Asselin B; Supko JG; Devidas M; Kaiser NA; Plourde P; Winick NJ; Reaman GH; Raetz E; Carroll WL; Hunger SP
    Blood; 2013 Jul; 122(4):507-14. PubMed ID: 23741010
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Asparaginase treatment in infants with acute lymphoblastic leukemia; pharmacokinetics and asparaginase hypersensitivity in Interfant-06.
    Albertsen BK; Harila-Saari A; Jahnukainen K; Lähteenmäki P; Riikonen P; Möttönen M; Lausen B
    Leuk Lymphoma; 2019 Jun; 60(6):1469-1475. PubMed ID: 30632847
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PEG-asparaginase.
    Fu CH; Sakamoto KM
    Expert Opin Pharmacother; 2007 Aug; 8(12):1977-84. PubMed ID: 17696798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. l-asparaginase loaded red blood cells in refractory or relapsing acute lymphoblastic leukaemia in children and adults: results of the GRASPALL 2005-01 randomized trial.
    Domenech C; Thomas X; Chabaud S; Baruchel A; Gueyffier F; Mazingue F; Auvrignon A; Corm S; Dombret H; Chevallier P; Galambrun C; Huguet F; Legrand F; Mechinaud F; Vey N; Philip I; Liens D; Godfrin Y; Rigal D; Bertrand Y
    Br J Haematol; 2011 Apr; 153(1):58-65. PubMed ID: 21332712
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A pharmacoeconomic analysis of pegaspargase versus native Escherichia coli L-asparaginase for the treatment of children with standard-risk, acute lymphoblastic leukemia: the Children's Cancer Group study (CCG-1962).
    Kurre HA; Ettinger AG; Veenstra DL; Gaynon PS; Franklin J; Sencer SF; Reaman GH; Lange BJ; Holcenberg JS
    J Pediatr Hematol Oncol; 2002; 24(3):175-81. PubMed ID: 11990302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of Erwinia asparaginase for adult patients with acute lymphoblastic leukemia after pegaspargase intolerance.
    Horvat TZ; Pecoraro JJ; Daley RJ; Buie LW; King AC; Rampal RK; Tallman MS; Park JH; Douer D
    Leuk Res; 2016 Nov; 50():17-20. PubMed ID: 27631159
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.